Literature DB >> 27392435

Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress.

Jun Lu1, Jian Chen2, Nianjun Xu3, Jun Wu4, Yani Kang5, Tingting Shen6, Hualei Kong7, Chao Ma8, Ming Cheng9, Zhifeng Shao10, Ling Xu11, Xiaodong Zhao12.   

Abstract

Application of cisplatin (DDP) for treating lung cancer is restricted due to its toxicity and lung cancer's drug resistance. In this study, we examined the effect of Jinfukang (JFK), an effective herbal medicine against lung cancer, on DDP-induced cytotoxicity in lung cancer cells. Morphologically, we observed that JFK increases DDP-induced pro-apoptosis in A549 cells in a synergistic manner. Transcriptome profiling analysis indicated that the combination of JFK and DDP regulates genes involved in apoptosis-related signaling pathways. Moreover, we found that the combination of JFK and DDP produces synergistic pro-apoptosis effect in other lung cancer cell lines, such as NCI-H1975, NCI-H1650, and NCI-H2228. Particularly, we demonstrated that AIFM2 is activated by the combined treatment of JFK and DDP and partially mediates the synergistic pro-apoptosis effect. Collectively, this study not only offered the first evidence that JFK promotes DDP-induced cytotoxicity, and activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress, but also provided a novel insight for improving cytotoxicity by combining JFK with DDP to treat lung cancer cells.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  AIFM2; Apoptosis; Cisplatin; Cytotoxicity; Jinfukang; Lung cancer; Transcriptome

Mesh:

Substances:

Year:  2016        PMID: 27392435     DOI: 10.1016/j.toxlet.2016.07.002

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  14 in total

1.  The microRNA-3622 family at the 8p21 locus exerts oncogenic effects by regulating the p53-downstream gene network in prostate cancer progression.

Authors:  Yue Zhang; Zhifang Xu; Wen Wen; Zhichao Liu; Chao Zhang; Ming Li; Fengping Hu; Shi Wei; Sejong Bae; Jiangbing Zhou; Runhua Liu; Lizhong Wang
Journal:  Oncogene       Date:  2022-05-02       Impact factor: 8.756

2.  Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells.

Authors:  Jun Lu; Wei Xu; Jie Qian; Shuyuan Wang; Bo Zhang; Lele Zhang; Rong Qiao; Minjuan Hu; Yiming Zhao; Xiaodong Zhao; Baohui Han
Journal:  BMC Med Genomics       Date:  2019-03-13       Impact factor: 3.063

3.  Herbal formula YYJD inhibits tumor growth by inducing cell cycle arrest and senescence in lung cancer.

Authors:  Tingting Zheng; Zujun Que; Lijing Jiao; Yani Kang; Yabin Gong; Jialin Yao; Chao Ma; Ling Bi; Qihan Dong; Xiaodong Zhao; Ling Xu
Journal:  Sci Rep       Date:  2017-07-10       Impact factor: 4.379

4.  Genome-Wide Profiling Reveals That Herbal Medicine Jinfukang-Induced Polyadenylation Alteration Is Involved in Anti-Lung Cancer Activity.

Authors:  Yao Kou; Guoqing Li; Jinhui Shao; Cong Liu; Jun Wu; Jun Lu; Xiaodong Zhao; Jing Tian
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-01       Impact factor: 2.629

5.  A TCM Formula YYWY Inhibits Tumor Growth in Non-Small Cell Lung Cancer and Enhances Immune-Response Through Facilitating the Maturation of Dendritic Cells.

Authors:  Bei Zhao; Xiaodan Hui; Lijing Jiao; Ling Bi; Lei Wang; Piao Huang; Wenxiao Yang; Yinan Yin; Shenyi Jin; Chengyan Wang; Xue Zhang; Ling Xu
Journal:  Front Pharmacol       Date:  2020-06-09       Impact factor: 5.810

6.  ATF6 aggravates acinar cell apoptosis and injury by regulating p53/AIFM2 transcription in Severe Acute Pancreatitis.

Authors:  Jie-Hui Tan; Rong-Chang Cao; Lei Zhou; Zhi-Tao Zhou; Huo-Ji Chen; Jia Xu; Xue-Mei Chen; Yang-Chen Jin; Jia-Yu Lin; Jun-Ling Zeng; Shu-Ji Li; Min Luo; Guo-Dong Hu; Xiao-Bing Yang; Jin Jin; Guo-Wei Zhang
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

7.  Jinfukang induces cellular apoptosis through activation of Fas and DR4 in A549 cells.

Authors:  Jun Lu; Jian Chen; Yani Kang; Jun Wu; Hui Shi; Yanli Fu; Lijing Jiao; Changsheng Dong; Xiaowei Li; Yu Jin; Wei Zhao; Ling Xu; Xiaodong Zhao
Journal:  Oncol Lett       Date:  2018-07-16       Impact factor: 2.967

8.  Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line.

Authors:  Jun Lu; Qin Shi; Lele Zhang; Jun Wu; Yuqing Lou; Jie Qian; Bo Zhang; Shuyuan Wang; Huimin Wang; Xiaodong Zhao; Baohui Han
Journal:  Front Oncol       Date:  2019-09-11       Impact factor: 6.244

9.  Herbal formula Yangyinjiedu induces lung cancer cell apoptosis via activation of early growth response 1.

Authors:  Wenxiao Yang; Yani Kang; Qiang Zhao; Ling Bi; Lijing Jiao; Yunzhao Gu; Jun Lu; Jialin Yao; Di Zhou; Jielin Sun; Xiaodong Zhao; Ling Xu
Journal:  J Cell Mol Med       Date:  2019-06-25       Impact factor: 5.310

10.  Could Jinfukang alleviate the chemotherapy-related adverse effects in non-small cell lung cancer patients?: A protocol for a double-blind, randomized controlled trial.

Authors:  Xing Zheng; Wenmin Wang; Gefei Wang; Shenghua Liu
Journal:  Medicine (Baltimore)       Date:  2021-07-16       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.